aderbasib aderbasib aderbasib (codenamed incb7839) is a sheddase inhibitor that may suppress tumor cell proliferation. acting on multiple receptor classes and subclasses, aderbasib is observed to regulate the tumor necrosis factor of cancer cells. aderbasib was being developed by incyte as a potential adjunctive treatment for metastatic breast cancer. development was halted in 2011 after positive findings from phase ii trials were contradicted by further research. aderbasibclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status investigational identifiers iupac name methyl (6s,7s)-7-(hydroxycarbamoyl)-6--5-azaspirooctane-5-carboxylate cas number791828-58-5pubchem cid16070111chemspider17229620uniiv9yl6nej3gkeggd09320chemblchembl1376060comptox dashboard (epa)dtxsid701000327 chemical and physical dataformulac21h28n4o5molar mass416.478 g·mol−13d model (jsmol)interactive image smiles coc(=o)n1cc2(cc2)c(1c(=o)n3ccn(cc3)c4=cc=cc=c4)c(=o)no inchi inchi=1s/c21h28n4o5/c1-30-20(28)25-14-21(7-8-21)13-16(18(26)22-29)17(25)19(27)24-11-9-23(10-12-24)15-5-3-2-4-6-15/h2-6,16-17,29h,7-14h2,1h3,(h,22,26)/t16-,17-/m0/s1key:djxmszszeiklqz-irxdydnusa-n